×
Hero Background

Granulocyte Macrophage Colony Stimulating Factor Companies

ID: MRFR/Pharma/4951-HCR
100 Pages
Rahul Gotadki
October 2025

Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) is a naturally occurring protein in the body that stimulates the production and function of white blood cells, including granulocytes and macrophages. GM-CSF is used therapeutically in medicine to boost the immune system, particularly in individuals undergoing certain medical treatments. Companies involved in GM-CSF development and manufacturing play a crucial role in providing therapeutic solutions.

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Granulocyte-Macrophage Colony-Stimulating Factor Market Research Report – Forecast to 2035 Infographic
Summary Table of Contents Segmentation Download PDF

Top Industry Leaders in the Granulocyte Macrophage Colony Stimulating Factor Market

Granulocyte-Macrophage Colony-Stimulating Factor Key Companies

 

Latest Granulocyte-Macrophage Colony-Stimulating Factor Companies Update



Chugai Pharmaceutical The leading manufacturer of filgrastim (Granulocyte) announced plans to expand their global production capacity due to increasing demand for the GM-CSF therapy.


Coherus BioSciences Received US FDA approval for Udencya, a biosimilar version of pegfilgrastim, offering a more affordable alternative for managing chemotherapy-induced neutropenia.


Kyowa Hakko Kirin Developed a long-acting GM-CSF variant (NKTR-102) in collaboration with Nektar Therapeutics, demonstrating promising efficacy in clinical trials for neutropenia prevention.


List of Granulocyte-Macrophage Colony-Stimulating Factor Key Companies in the Market



  • Xconomy Inc.

  • Partner Therapeutics (PTx)

  • Sanofi-Aventis U.S. LLC

  • Novartis AG

  • Thermo Fisher Scientific

  • Merck KGaA